https://deceraclinical.com/education/activities/oncology/bcl2aetool/27503/content
Managing Adverse Events Associated With BCL-2 Inhibitors for Hematologic Malignancies | Decera...
An interactive decision support tool designed to help HCPs manage adverse events associated with BCL-2 inhibitors in CLL, SLL, and AML from Clinical Care...
for hematologic malignanciesadverse eventsassociated with
https://adisinsight.springer.com/trials/700392338?error=cookies_not_supported&code=a8b8cd6b-ac92-4095-ac8d-cd4e708097b0
A clinical study to evaluate 6MW5311 for hematologic malignancies, specifically Acute Myeloid...
Aim to evaluate 6MW5311 for hematologic malignancies, specifically Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Multiple Myeloma
for hematologic malignanciesclinical study
https://www.chuv.ch/en/hematologie/hem-home/recherche/translational-research-unit/targeted-immunotherapies-for-hematologic-malignancies
Targeted immunotherapies for hematologic malignancies - Service et Laboratoire central...
for hematologic malignanciestargetedservicelaboratoirecentral
https://www.cancernetwork.com/view/fda-approves-ruxolitinib-tablets-for-hematologic-malignancies
FDA Approves Ruxolitinib Tablets for Hematologic Malignancies | CancerNetwork
May 10, 2026 - Data showing the bioequivalence of extended-release ruxolitinib tablets vs reference ruxolitinib supported the FDA approval across multiple indications.
for hematologic malignanciesfdaapprovesruxolitinibtablets
https://genomictestingcooperative.com/genomic-tests/hematology-genes/
DNA GENES For Hematologic Malignancies Profiling
Jun 28, 2024 - Our testing covers all well defined, clinically relevant genes. BCR-ABL, FLT3, PML-RARA, JAK2, CALR, NPM1, ASXL1, RUNX1, TP53, IDH1, IDH2, MYC, MYD88
for hematologic malignanciesdnagenesprofiling